The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2025 | Optimizing bridging therapy prior to CAR T-cell therapy in multiple myeloma
Doris Hansen, MD, Moffitt Cancer Center, Tampa, FL, comments on the importance of bridging therapy prior to CAR T-cell therapy in multiple myeloma, emphasizing that individualized approaches based on patient characteristics and treatment history are crucial for improving safety and efficacy profiles. Dr Hansen highlights the potential of talquetamab as a bridging therapy in late-line settings. This interview took place at the 22nd International Myeloma Society (IMS) Annual Meeting in Toronto, Canada.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So I think bridging therapy is a very important aspect of CAR T-cell therapy. We have seen time and again that reducing disease burden or debulking the disease prior to CAR-T will effectively improve safety and efficacy profile for these patients. Though I don’t know that there’s one approach that fits all. Bridging therapy must be individualized based on patient characteristics, comorbidities, their treatment and response history...
So I think bridging therapy is a very important aspect of CAR T-cell therapy. We have seen time and again that reducing disease burden or debulking the disease prior to CAR-T will effectively improve safety and efficacy profile for these patients. Though I don’t know that there’s one approach that fits all. Bridging therapy must be individualized based on patient characteristics, comorbidities, their treatment and response history. Certainly in the earlier utilization of CAR-T in earlier lines, we have many bridging therapy options, but in later lines, there are some recent data published from Dr Dhakal and the Myeloma Consortium, immunotherapy consortium, looking at talquetamab as a potential bridge in the late-line setting and has shown incredible results in terms of efficacy and safety and resolution of nearly all on-target off-tumor events.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
My COIs: D.K.H is supported by the NCI (R01CA281756-01A1) and the Pentecost Family Myeloma Research Center. D.K.H reports research funding from Bristol-Myers Squibb, Janssen, Karyopharm, Kite Pharma, and Adaptive Biotech; Consulting.
